FIELD: biotechnology.
SUBSTANCE: peptide ligand is described specific for human kallikrein, which includes a polypeptide containing at least three reactive groups separated by sequences of at least two loops, and molecular backbone forming covalent bonds with reactive groups of a polypeptide with the formation on the molecular backbone of at least two loops ofpolypeptide, peptide ligand loops include five amino acids and one loop contains a fragment GrA(ψCH2NH)HQ/TxLGr, where Gr means reactive group. Pharmaceutical composition containing said peptide is also described and the use of said peptide for the treatment of conditions mediated by kallikrein selected from inflammatory conditions is presented, allergic hypersensitivity, cancer, bacterial or viral infection, ophthalmologic disorders and autoimmune disorders.
EFFECT: invention expands the arsenal of means of treating diseases, mediated by kallikrein.
12 cl, 23 dwg, 27 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
MODULATION OF STRUCTURED PROTEINS SPECIFICITY | 2012 |
|
RU2631931C2 |
MODULATING THE SPECIFICITY OF STRUCTURED PROTEINS | 2012 |
|
RU2745572C2 |
NOVEL POLYPEPTIDES | 2014 |
|
RU2674604C2 |
BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2015 |
|
RU2708459C2 |
MODIFIED ANTI-EGFR ANTIBODIES WITH REDUCED AMMONOGENICITY | 2002 |
|
RU2297245C2 |
FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
VARIANTS OF Fc WITH CHANGED BINDING WITH FcRn | 2014 |
|
RU2700882C2 |
Fc VERSIONS WITH MODIFIED BINDING WITH FcRn | 2008 |
|
RU2529951C2 |
Fc-REGION OPTION | 2014 |
|
RU2757124C2 |
MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
Authors
Dates
2018-12-04—Published
2014-04-11—Filed